It is hoped that the use of tau antibodies such as TOC1, T22, TOMA, and pS422, which selectively recognize dimers and higher order oligomers, will allow convincingly demonstrating the real toxic effect of tau oligomers on a number of cellular processes in tauopathies. This evidence concerns the gene MAPT and tauopathy.